Aurinia Pharmaceuticals Inc.

NasdaqGM:AUPH Rapport sur les actions

Capitalisation boursière : US$1.3b

Aurinia Pharmaceuticals Dividendes et rachats

Dividende contrôle des critères 0/6

Aurinia Pharmaceuticals n'a pas d'antécédents de versement de dividendes.

Informations clés

n/a

Rendement du dividende

1.3%

Rendement des rachats

Rendement total pour l'actionnaire1.3%
Rendement futur des dividendesn/a
Croissance des dividendesn/a
Prochaine date de paiement du dividenden/a
Date ex-dividenden/a
Dividende par actionn/a
Ratio de distributionn/a

Mises à jour récentes sur les dividendes et les rachats

Recent updates

Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon

Nov 08

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Surges 30% Yet Its Low P/S Is No Reason For Excitement

Sep 06
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Surges 30% Yet Its Low P/S Is No Reason For Excitement

Aurinia Pharmaceuticals Appears Undervalued

Jul 05

We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow

May 24
We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow

Analysts Have Made A Financial Statement On Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) First-Quarter Report

May 05
Analysts Have Made A Financial Statement On Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) First-Quarter Report

Aurinia Pharma: A Welcome Change To The Thesis (Rating Upgrade)

May 02

Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024

Apr 18

Aurinia Pharma: Cheaper Now, But Buyout Hopes Dashed

Mar 05

Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target After Its Latest Report

Feb 19
Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target After Its Latest Report

Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) 26% Dip In Price Shows Sentiment Is Matching Revenues

Feb 17
Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) 26% Dip In Price Shows Sentiment Is Matching Revenues

Aurinia Pharmaceuticals 2023 Earnings Review: Calling 'Time' In Last Chance Saloon

Feb 15

Aurinia Pharmaceuticals: Sales Growth Would Help Buyout Potential

Jan 28

We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow

Jan 05
We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow

Insufficient Growth At Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Hampers Share Price

Dec 18
Insufficient Growth At Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Hampers Share Price

Aurinia Pharmaceuticals (NASDAQ:AUPH) Is In A Strong Position To Grow Its Business

Sep 14
Aurinia Pharmaceuticals (NASDAQ:AUPH) Is In A Strong Position To Grow Its Business

Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Low P/S No Reason For Excitement

Jun 11
Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Low P/S No Reason For Excitement

Broker Revenue Forecasts For Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Are Surging Higher

May 09
Broker Revenue Forecasts For Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Are Surging Higher

We're Not Worried About Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn

May 01
We're Not Worried About Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Just Trimmed Their Revenue Forecasts By 26%

Nov 04
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Just Trimmed Their Revenue Forecasts By 26%

Aurinia Pharmaceuticals wins European approval of Lupkynis for lupus

Sep 19

Stabilité et croissance des paiements

Récupération des données sur les dividendes

Dividende stable: Données insuffisantes pour déterminer si les dividendes par action de AUPH ont été stables dans le passé.

Dividende croissant: Données insuffisantes pour déterminer si les paiements de dividendes de AUPH ont augmenté.


Rendement des dividendes par rapport au marché

Aurinia Pharmaceuticals Rendement des dividendes par rapport au marché
Comment le rendement du dividende de AUPH se compare-t-il à celui du marché ?
SegmentRendement du dividende
Entreprise (AUPH)n/a
25% du marché (US)1.3%
25% du marché (US)4.2%
Moyenne du secteur (Biotechs)2.3%
Analyste prévisionnel (AUPH) (jusqu'à 3 ans)n/a

Dividende notable: Impossible d'évaluer le rendement des dividendes de AUPH par rapport aux 25 % les moins bien payés par les actionnaires, car la société n'a signalé aucun versement récent.

Dividende élevé: Impossible d'évaluer le rendement des dividendes de AUPH par rapport aux 25 % des principaux payeurs de dividendes, car la société n'a signalé aucun versement récent.


Bénéfice distribué aux actionnaires

Couverture des revenus: Données insuffisantes pour calculer le ratio de distribution de AUPH afin de déterminer si les dividendes versés sont couverts par les bénéfices.


Paiement en espèces aux actionnaires

Couverture des flux de trésorerie: Impossible de calculer la durabilité des dividendes car AUPH n'a signalé aucun versement.


Découvrir des entreprises qui versent des dividendes élevés